Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

BMS-817399

Alternative Names: bms-817399
Latest Update: 2022-10-03
Latest Update Note: PubMed Publication

Product Description

BMS-817399 is a CC-chemokine receptor-1 (CCR1) antagonist, which has been shown to inhibit cell-based functions driven by CCR1.

Mechanisms of Action: CCR1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2011-002024-40

P2

Completed

Arthritis, Rheumatoid

2013-02-13

RA

P2

Completed

Arthritis, Rheumatoid

2013-02-01

IM126001

P1

Completed

Arthritis, Rheumatoid

None

Recent News Events

Date

Type

Title

10/03/2022

PubMed

 Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them.

03/09/2020

PubMed

 Investigation on the Effect of Capillary Microsampling on Hematologic and Toxicokinetic Evaluation in Regulatory Safety Studies in Mice.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions